FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
09/11/2024
Voltar para busca
Dado oficial do USPTO
STIPE THERAPEUTICS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
STIPE THERAPEUTICS
ST13
US500000079363664Classe
1, 5, 42
Pedido
79363664
Registro
7341867
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
32
Atualização mais recente
09/11/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42
Data de depósito
29/06/2022
Data de registro
02/04/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
02/04/2024
Última transação
02/04/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
66
Localização do titular
DK
Examinador
BIBB, SCOTT
Unidade examinadora
L90
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
S. A. (pessoa física)
Representantes
Shoko Naruo Thompson Coburn LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicals for use in industry and science; chemicals for use in manufacture of peptidessmall moleculesa wide variety of goods; biological preparations for use in industry and science; biological preparations for use in manufacture; chemicals and chemical preparations for use in the manufacture of pharmaceuticals; chemicals and chemical preparations for use in the pharmaceutical industryactive chemical ingredients for use in the manufacture of pharmaceuticals for treating cancertumorigenesisautoimmune disordersother inflammatory diseases; chemicals and chemical preparations for use in biotechnological manufacturing processes; chemical and chemical preparations for use in biotechnological product development; chemicals and chemical preparations for use in the biotechnological industry; reagents for scientific purposes; reagents for medical research; enzymes for scientific purposes; enzymes for use in the manufacture of pharmaceuticals; biological preparations other than for medical use; proteins for use in industry and science; proteins for use in manufacture; peptides for use in industry and science; peptides for use in manufacture of pharmaceuticals
Classe 5
Pharmaceutical preparations for the prevention of cancertumorigenesisautoimmune disordersother inflammatory diseasesmedical preparations for the treatment of cancertumorigenesisautoimmune disordersother inflammatory diseasesveterinary pharmaceutical preparations for the treatment of cancertumorigenesisautoimmune disordersother inflammatory diseases; medical preparationsadjuvants used in vaccines; sanitary preparations for medical purposes; dietetic food and preparations adapted for medical or veterinary usefood for babies; dietary supplements for human beings and animals; material for stopping teethdental wax; disinfectants; preparations for destroying vermin; fungicidesherbicides; pharmaceuticals for the treatment of cancer and autoimmune disorders; drug delivery agents in the form of intravenous administration fluids that facilitate the delivery of pharmaceutical preparations; synthetic proteins and peptides for pharmaceutical and medical purposesfor the treatment of cancertumorigenesisautoimmune disordersother inflammatory diseases; regulatory proteins and peptides for pharmaceutical and medical useprotein arrays for treating cancertumorigenesisautoimmune disordersother inflammatory diseases
Classe 42
Design and development of computer hardware and software; clinical research in the field of cancertumorigenesisautoimmune disordersother inflammatory diseases; medical and scientific researchconducting clinical trials for others; drug discovery services; development of pharmaceutical preparations and medicines; research relating to medicines; medical and pharmacological research services; medical laboratories; scientific and technological servicesresearch and design in the field of medical technology; product design and development of medical apparatus; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing medical and scientific research information relating to medical and veterinary research and development
Publicações
Histórico de despachos e eventos da marca no USPTO.
32 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
18/10/2024
FIMP
FINAL DISPOSITION PROCESSED
18/10/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/07/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
02/04/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
02/04/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
16/01/2024
PUBO
PUBLISHED FOR OPPOSITION
16/01/2024
GPNX
NOTIFICATION PROCESSED BY IB
13/01/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
27/12/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
27/12/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
27/12/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
13/12/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
16/11/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
16/11/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
16/11/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
13/11/2023
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
13/11/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
13/11/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
13/11/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
13/11/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
13/11/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
06/10/2023
RFNT
REFUSAL PROCESSED BY IB
26/06/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/06/2023
RFRR
REFUSAL PROCESSED BY MPU
07/06/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
18/04/2023
CNRT
NON-FINAL ACTION WRITTEN
17/04/2023
DOCK
ASSIGNED TO EXAMINER
13/04/2023
MAFR
APPLICATION FILING RECEIPT MAILED
01/03/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
25/02/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
24/02/2023
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace STIPE THERAPEUTICS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.